The efficacy of vitamin E against oxidative damage and autoantibody production in systemic lupus erythematosus: a preliminary study.
The hypothesis that reactive oxygen species (ROS) modification of DNA is involved in the development of autoantibodies in systemic lupus erythematosus (SLE) is supported by the enhanced reactivity of anti-DNA antibodies to ROS-denatured DNA. We studied the efficacy of vitamin E against both oxidative DNA damage and autoantibody production in SLE. Urinary 8-hydroxydeoxyguanosine (8-OHdG), an indicator of oxidative DNA damage, and the anti-double-stranded DNA (anti-ds DNA) antibody, a predictor of disease activity, were assayed twice, first during the season with the most intense sunlight and then later in the year. Twelve women among 36 outpatients received vitamin E (150 to 300 mg/day) together with prednisolone (PSL). No significant age or daily dose of PSL differences were evident between patient groups. Urinary 8-OHdG in the PSL with vitamin E group (15.0 +/- 10.2 ng/mg during the period of intense sunlight and 11.7 +/- 8.7 ng/mg during the remainder of the year) did not differ significantly from that in the PSL without vitamin E group (20.0 +/- 23.2 and 11.0 +/- 5.9 ng/mg, at these respective times), but the anti-ds DNA antibody titer in the PSL with vitamin E group (17.9 +/- 20.3 IU/l during the period of intense sunlight and 16.3 +/- 19.4 IU/l during the remainder of the year) was significantly lower than that in the PSL without vitamin E group for both sunlight-defined periods (66.3 +/- 76.8 and 55.8 +/- 59.0 IU/l, at these respective times; P < 0.05). The present study suggests that vitamin E can suppress autoantibody production via a mechanism independent of antioxidant activity.
Maeshima
Etsuko
E
Third Department of Internal Medicine, Wakayama Medical University, 811-1 Kimiidera, Wakayama, Wakayama, 641-0012, Japan. etsukom@ouhs.ac.jp
Liang
Xiang-Ming
XM
Goda
Mikako
M
Otani
Haruhisa
H
Mune
Masatoshi
M
D000328:Adult; D000975:Antioxidants / Q000627:therapeutic use*; D001323:Autoantibodies / Q000187:drug effects*; D004249:DNA Damage; D005260:Female; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy* / Q000276:immunology; D008875:Middle Aged; D018384:Oxidative Stress; D010865:Pilot Projects; D017382:Reactive Oxygen Species; D012621:Seasons; D013472:Sunlight / Q000009:adverse effects*; D014810:Vitamin E / Q000627:therapeutic use*
D000975:Antioxidants; D001323:Autoantibodies; D017382:Reactive Oxygen Species; D014810:Vitamin E